At Sirnaomics, as a pioneer in siRNA therapeutics and a publicly traded company, we recognise that precision delivery is the cornerstone of effective RNAi treatments. Our proprietary PNP (Polymer Nanoparticle) and GalNAc platforms are designed to overcome the challenges of tissue-specific targeting, particularly in complex diseases like cancer and fibrosis. The PNP platform enhances tumor penetration, while GalNAc ensures hepatocyte-specific delivery, both critical for minimising off-target effects. With chemical modifications to improve stability and reduce immunogenicity, our technologies set a new standard for siRNA delivery, particularly in oncology space. As a leader in this space, Sirnaomics is also open to licensing these cutting-edge platforms to other siRNA developers, enabling broader advancements in the field.

The next five years will see transformative advancements in RNA therapeutics, and Sirnaomics is at the forefront of this evolution. Beyond liver and oncology applications, we are pioneering siRNA delivery for CNS and cardiac diseases, leveraging novel conjugates platforms like Antibody Oligo Drug Conjudates (AODC). The integration of AI for sequence optimisation and combo therapies (e.g., siRNA + CRISPR) will further accelerate progress. As a publicly traded innovator, Sirnaomics is committed to shaping the future of RNAi, through internal R&D and strategic partnerships. Our open approach to licensing ensures that our technologies can empower the entire siRNA ecosystem.